NL300694I1 - - Google Patents

Info

Publication number
NL300694I1
NL300694I1 NL300694C NL300694C NL300694I1 NL 300694 I1 NL300694 I1 NL 300694I1 NL 300694 C NL300694 C NL 300694C NL 300694 C NL300694 C NL 300694C NL 300694 I1 NL300694 I1 NL 300694I1
Authority
NL
Netherlands
Application number
NL300694C
Other languages
Dutch (nl)
Other versions
NL300694I2 (en:Method
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35242158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300694(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NL300694I1 publication Critical patent/NL300694I1/nl
Publication of NL300694I2 publication Critical patent/NL300694I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
NL300694C 2004-04-27 2014-10-02 NL300694I2 (en:Method)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56562304P 2004-04-27 2004-04-27
PCT/US2005/014386 WO2005104745A2 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists

Publications (2)

Publication Number Publication Date
NL300694I1 true NL300694I1 (en:Method) 2015-12-29
NL300694I2 NL300694I2 (en:Method) 2015-12-29

Family

ID=35242158

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300694C NL300694I2 (en:Method) 2004-04-27 2014-10-02

Country Status (38)

Country Link
US (9) US7498440B2 (en:Method)
EP (3) EP2570128B1 (en:Method)
JP (2) JP5014121B2 (en:Method)
KR (2) KR101152032B1 (en:Method)
CN (2) CN1976701A (en:Method)
AP (1) AP2213A (en:Method)
AR (1) AR050902A1 (en:Method)
AU (1) AU2005237576B2 (en:Method)
BE (1) BE2014C063I2 (en:Method)
BR (1) BRPI0510170B8 (en:Method)
CA (2) CA2564742C (en:Method)
CY (3) CY1113196T1 (en:Method)
DK (2) DK2570128T3 (en:Method)
EA (2) EA015033B1 (en:Method)
EC (1) ECSP066940A (en:Method)
ES (2) ES2600405T3 (en:Method)
FR (1) FR14C0075I2 (en:Method)
HR (2) HRP20120832T1 (en:Method)
HU (2) HUE031304T2 (en:Method)
IL (1) IL178152A (en:Method)
LT (1) LT2570128T (en:Method)
LU (1) LU92565I2 (en:Method)
MA (1) MA28631B1 (en:Method)
MX (1) MXPA06012405A (en:Method)
MY (1) MY144753A (en:Method)
NL (1) NL300694I2 (en:Method)
NO (3) NO338959B1 (en:Method)
NZ (1) NZ549997A (en:Method)
PE (1) PE20060259A1 (en:Method)
PL (2) PL1740177T3 (en:Method)
PT (2) PT2570128T (en:Method)
SG (1) SG186597A1 (en:Method)
SI (2) SI1740177T1 (en:Method)
TW (1) TWI363759B (en:Method)
UA (1) UA95768C2 (en:Method)
UY (1) UY28871A1 (en:Method)
WO (1) WO2005104745A2 (en:Method)
ZA (1) ZA200608565B (en:Method)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050250A1 (es) * 2003-07-17 2005-04-08 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
CA2542636A1 (en) * 2003-10-17 2005-04-28 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists field of the invention
TW200524577A (en) * 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005087236A1 (en) * 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
JP2007529513A (ja) * 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
US20070185148A1 (en) * 2004-03-17 2007-08-09 Glaxo Group Limited M3 muscarinic acetylchoine receptor antagonists
JP2007531792A (ja) * 2004-04-05 2007-11-08 サマリタン，ファーマスーティカルス，インク． 抗ｈｉｖキヌクリジン化合物
TWI363759B (en) 2004-04-27 2012-05-11 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
JP2007537261A (ja) * 2004-05-13 2007-12-20 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
WO2006055553A2 (en) * 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2007016639A2 (en) * 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US7767691B2 (en) * 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
WO2007122165A1 (en) 2006-04-20 2007-11-01 Glaxo Group Limited Novel compounds
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
AU2007280214A1 (en) 2006-08-01 2008-02-07 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
CL2009000250A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo[3,4-b]piridina carboxamida; composicion farmaceutica que los comprende; y su uso en el tratamiento del asma, epoc y rinitis.
AR070563A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Compuesto de un biciclo condensado pirazol-piridin-amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de enfermedades respiratorias.
TW200946526A (en) 2008-02-06 2009-11-16 Glaxo Group Ltd Dual pharmacophores-PDE4-muscarinic antagonistics
JP5502077B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規な化合物
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
US11116721B2 (en) 2009-02-26 2021-09-14 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
UA101098C2 (xx) 2009-04-30 2013-02-25 Глаксо Груп Лимитед Заміщені оксазолом індазоли як інгібітори pi3-кінази$замещенные оксазолом индазолы как ингибиторы pi3-киназы
WO2011029896A1 (en) 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
EP2507226A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
EP2507223A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
US8742131B2 (en) * 2010-01-28 2014-06-03 Theron Pharmaceuticals, Inc. 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
EP2585047A1 (en) * 2010-06-22 2013-05-01 Chiesi Farmaceutici S.p.A. Dry powder formulation comprising an antimuscarinic drug
PL2614058T3 (pl) 2010-09-08 2015-12-31 Glaxosmithkline Ip Dev Ltd Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
CN103582477A (zh) * 2011-06-08 2014-02-12 葛兰素集团有限公司 包含芜地溴铵和皮质类固醇的组合
KR20140041700A (ko) 2011-06-08 2014-04-04 글락소 그룹 리미티드 우메클리디늄을 포함하는 건조 분말 흡입기 조성물
RU2666963C2 (ru) 2012-04-13 2018-09-13 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Агрегированные частицы
RU2502743C1 (ru) * 2012-08-03 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору
US9273001B2 (en) * 2012-08-15 2016-03-01 Glaxo Group Limited Chemical process
GB201222679D0 (en) * 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
US9751875B2 (en) 2013-07-13 2017-09-05 Beijing Fswelcome Technology Development Co., Ltd. Quinine compounds, and optical isomers, preparation method and medical use thereof
EP3027184A1 (en) 2013-07-30 2016-06-08 GlaxoSmithKline Intellectual Property Development Limited Topical compositions for treatment of excessive sweating and methods of use thereof
CA2923995A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
EP3057588A1 (en) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
CR20160529A (es) 2014-05-12 2017-01-02 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmacéuticas para tratar enfermedades infecciosas
EP4252742A3 (en) 2014-05-28 2023-12-27 GlaxoSmithKline Intellectual Property Development Ltd Fluticasone furoate in the treatment of copd
EP3215489B1 (en) * 2014-11-03 2019-07-24 OLON S.p.A. Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN105461710A (zh) * 2015-10-23 2016-04-06 安徽德信佳生物医药有限公司 一种芜地溴铵的制备方法
US10835514B2 (en) * 2016-01-08 2020-11-17 Theron Pharmaceuticals, Inc. Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN107200734B (zh) * 2016-03-18 2019-12-24 益方生物科技（上海）有限公司 奎宁环衍生物及其制备方法和用途
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
JP2019524792A (ja) 2016-08-08 2019-09-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 化合物
PT109740B (pt) 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
WO2018163212A1 (en) * 2017-03-08 2018-09-13 Gbr Laboratories Pvt. Ltd A process for the preparation of umeclidinium bromide and intermediates thereof
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
IT201700058796A1 (it) 2017-05-30 2018-11-30 Olon Spa Procedimento per la preparazione di un nuovo intermedio di sintesi dell’umeclidinio.
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
CN108558860B (zh) * 2018-06-04 2020-12-25 成都伊诺达博医药科技有限公司 一种合成芜地溴铵的方法
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
PT115583B (pt) 2019-06-17 2022-05-02 Hovione Farm S A Processo contínuo para a preparação de medicamentos anticolinérgicos
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
WO2021191875A1 (en) 2020-03-26 2021-09-30 Glaxosmithkline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections
CN111484445B (zh) * 2020-04-21 2021-05-18 广东莱佛士制药技术有限公司 分离纯化高纯度乌美溴铵的中间体的方法
WO2021218833A1 (zh) * 2020-04-26 2021-11-04 北京硕佰医药科技有限责任公司 一种m受体拮抗剂的晶体、制备方法及其应用
IL301285A (en) 2020-09-10 2023-05-01 Precirix N V Antibody fragment against fap
CN112479983B (zh) * 2020-11-25 2022-07-12 江苏豪森药业集团有限公司 乌美溴铵中间体及其制备方法
PT117440B (pt) 2021-09-03 2024-04-26 Hovione Farm S A Processo para a preparação de aminas cíclicas cloroaquilo substituídas
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
EP4518911A1 (en) 2022-05-02 2025-03-12 Precirix N.V. Pre-targeting
WO2024251812A1 (en) 2023-06-07 2024-12-12 Pharmazell Gmbh A process for the preparation of umeclidinium bromide intermediate

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800478A (en) 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800481A (en) 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de) 1967-06-08 1972-04-25 Siemens Ag Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1230087A (en:Method) 1967-08-17 1971-04-28
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
US4627432A (en) 1982-10-08 1986-12-09 Glaxo Group Limited Devices for administering medicaments to patients
NZ217006A (en) 1985-07-30 1989-04-26 Glaxo Group Ltd Inhaler for finely divided medicament includes plunger to open medicament container
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5780466A (en) 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
US6350758B1 (en) 1996-12-02 2002-02-26 Georgetown University Tropane derivatives and method for their synthesis
US6248752B1 (en) 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
DK1353919T3 (da) * 2000-12-28 2006-11-20 Almirall Prodesfarma Ag Hidtil ukendte quinuclidinderivater og medicinale sammensætninger indeholdende samme
RU2004110717A (ru) 2001-10-17 2005-10-20 Юсиби, С.А. (Be) Производные хинуклидина, способы их получения и их применение в качестве и нгибиторов м2- и/или м3- мускариновых рецепторов
MXPA04004373A (es) * 2001-11-09 2004-08-11 Upjohn Co Compuestos heterociclicos condensados con fenilo azabiciclo para el tratamiento de enfermedades.
UA76571C2 (en) * 2001-12-20 2006-08-15 Derivatives of 1-alkyl-1-azoniabicyclo [2.2.2.]octanecarbamate and use thereof as antagonists of muscarin receptor
US6696462B2 (en) 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
UY27927A1 (es) 2002-08-06 2003-12-31 Glaxo Group Ltd Antagonistas del receptor muscarínico m3 de acetilcolina
JP2006522161A (ja) 2003-04-07 2006-09-28 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体拮抗剤
PE20050250A1 (es) 2003-07-17 2005-04-08 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
PE20050327A1 (es) 2003-07-17 2005-06-08 Glaxo Group Ltd Derivados de 8-azoniabiciclo[3.2.1]octano como antagonistas de los receptores muscarinicos de la acetilcolina
TW200519109A (en) 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
EP1677795B1 (en) 2003-10-14 2011-01-05 Glaxo Group Limited Muscarinic acetycholine receptor antagonists
CA2542636A1 (en) 2003-10-17 2005-04-28 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists field of the invention
TW200524577A (en) 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
ES2329586T3 (es) 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
AR046783A1 (es) 2003-12-03 2005-12-21 Glaxo Group Ltd Compuesto de sal ciclica de amonio cuaternario composicion farmaceutica que lo comprende y su uso para preparar esta ultima
UY28645A1 (es) 2003-12-03 2005-06-30 Glaxo Group Ltd Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
TW200534855A (en) 2004-01-13 2005-11-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
JP2007530451A (ja) 2004-03-11 2007-11-01 グラクソ　グループ　リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
WO2005087236A1 (en) 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
US20070185090A1 (en) 2004-03-17 2007-08-09 Jakob Busch-Petersen Muscarinic acetylchoine receptor antagonists
JP2007529513A (ja) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
WO2005094835A1 (en) 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US20070185148A1 (en) 2004-03-17 2007-08-09 Glaxo Group Limited M3 muscarinic acetylchoine receptor antagonists
WO2005099706A2 (en) 2004-04-07 2005-10-27 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
TWI363759B (en) * 2004-04-27 2012-05-11 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
JP2007537261A (ja) 2004-05-13 2007-12-20 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
JP2008501020A (ja) 2004-05-28 2008-01-17 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
EP1765339A4 (en) 2004-06-30 2009-09-02 Glaxo Group Ltd ANTAGONISTS OF MUSCARIN ACETYLCHOLIN RECEPTOR
JP2008509159A (ja) 2004-08-05 2008-03-27 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体拮抗薬
US20090076061A1 (en) 2004-08-06 2009-03-19 Jakob Busch-Petersen Muscarinic acetycholine receptor antagonists
JP2008518939A (ja) 2004-10-29 2008-06-05 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
WO2006055553A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2006055503A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
PE20061162A1 (es) 2004-12-06 2006-10-14 Smithkline Beecham Corp Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
PE20060826A1 (es) 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2007016639A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
JP2009503101A (ja) 2005-08-02 2009-01-29 グラクソ グループ リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
US7767691B2 (en) 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Also Published As

Publication number Publication date
EP1740177A4 (en) 2010-05-05
PE20060259A1 (es) 2006-03-25
US8575347B2 (en) 2013-11-05
EP2570128A1 (en) 2013-03-20
EP1740177B1 (en) 2012-08-08
NL300694I2 (en:Method) 2015-12-29
US9144571B2 (en) 2015-09-29
AU2005237576B2 (en) 2012-01-12
NO2017017I1 (no) 2017-05-04
US20130030015A1 (en) 2013-01-31
JP5398871B2 (ja) 2014-01-29
TW200605887A (en) 2006-02-16
TWI363759B (en) 2012-05-11
US7498440B2 (en) 2009-03-03
BRPI0510170A (pt) 2007-10-02
CY1113196T1 (el) 2015-12-09
KR20110010841A (ko) 2011-02-07
JP5014121B2 (ja) 2012-08-29
NO2017018I2 (no) 2018-05-14
HUS1400053I1 (hu) 2017-07-28
AP2213A (en) 2011-03-01
DK1740177T3 (da) 2012-10-29
CN102040602A (zh) 2011-05-04
FR14C0075I1 (fr) 2014-11-21
ECSP066940A (es) 2006-12-20
AP2006003746A0 (en) 2006-10-31
SG186597A1 (en) 2013-01-30
EP3111936A1 (en) 2017-01-04
MXPA06012405A (es) 2007-01-17
EA200601991A1 (ru) 2007-02-27
MY144753A (en) 2011-10-31
PT1740177E (pt) 2012-11-02
WO2005104745A2 (en) 2005-11-10
SI1740177T1 (sl) 2012-12-31
JP2007534769A (ja) 2007-11-29
US7488827B2 (en) 2009-02-10
US20120157491A1 (en) 2012-06-21
KR101037026B1 (ko) 2011-05-25
CY2014043I2 (el) 2015-12-09
US8853404B2 (en) 2014-10-07
HRP20120832T1 (hr) 2012-11-30
CA2755954A1 (en) 2005-11-10
NZ549997A (en) 2010-10-29
CN1976701A (zh) 2007-06-06
ZA200608565B (en) 2019-12-18
ES2392848T3 (es) 2012-12-14
IL178152A0 (en) 2006-12-31
LU92565I9 (en:Method) 2019-01-17
HK1102423A1 (en) 2007-11-23
NO20065417L (no) 2006-12-29
CA2755954C (en) 2014-02-18
WO2005104745A3 (en) 2006-08-03
US20090124653A1 (en) 2009-05-14
CA2564742A1 (en) 2005-11-10
FR14C0075I2 (fr) 2015-05-22
BE2014C063I2 (en:Method) 2024-08-08
US8309572B2 (en) 2012-11-13
HUE031304T2 (hu) 2017-07-28
PL1740177T3 (pl) 2012-12-31
UA95768C2 (ru) 2011-09-12
KR20070015412A (ko) 2007-02-02
AU2005237576A1 (en) 2005-11-10
ES2392848T4 (es) 2014-10-01
JP2012162559A (ja) 2012-08-30
CY2014043I1 (el) 2015-12-09
KR101152032B1 (ko) 2012-06-11
NO2017018I1 (no) 2017-05-04
CY1118082T1 (el) 2017-06-28
EA015033B1 (ru) 2011-04-29
US9045469B2 (en) 2015-06-02
LT2570128T (lt) 2016-10-10
BRPI0510170B8 (pt) 2021-05-25
EA201100019A1 (ru) 2011-12-30
MA28631B1 (fr) 2007-06-01
EP2570128B1 (en) 2016-08-10
LU92565I2 (fr) 2014-12-02
US20140371264A1 (en) 2014-12-18
PL2570128T3 (pl) 2017-09-29
US20070249664A1 (en) 2007-10-25
US20140080863A1 (en) 2014-03-20
US20070185155A1 (en) 2007-08-09
HRP20161385T1 (hr) 2016-12-02
US8183257B2 (en) 2012-05-22
BRPI0510170B1 (pt) 2018-12-18
AR050902A1 (es) 2006-12-06
NO338959B1 (no) 2016-11-07
US20150238470A1 (en) 2015-08-27
UY28871A1 (es) 2005-11-30
SI2570128T1 (sl) 2016-11-30
EP1740177A2 (en) 2007-01-10
IL178152A (en) 2011-05-31
ES2600405T3 (es) 2017-02-08
CA2564742C (en) 2012-01-10
PT2570128T (pt) 2016-10-07
DK2570128T3 (en) 2016-11-07
US20160002220A1 (en) 2016-01-07
EA021994B1 (ru) 2015-10-30

Similar Documents

Publication Publication Date Title
BE2024C508I2 (en:Method)
BE2023C542I2 (en:Method)
BE2022C549I2 (en:Method)
BE2021C001I2 (en:Method)
BE2020C513I2 (en:Method)
BE2020C517I2 (en:Method)
BE2019C540I2 (en:Method)
BE2019C523I2 (en:Method)
BE2019C548I2 (en:Method)
BE2019C506I2 (en:Method)
BE2020C525I2 (en:Method)
BE2017C063I2 (en:Method)
BE2017C027I2 (en:Method)
BE2017C023I2 (en:Method)
BE2017C002I2 (en:Method)
BE2016C067I2 (en:Method)
BE2016C014I2 (en:Method)
BE2015C041I2 (en:Method)
BE2015C038I2 (en:Method)
BE2015C014I2 (en:Method)
BE2014C071I2 (en:Method)
BE2015C015I2 (en:Method)
BE2014C064I2 (en:Method)
LU92565I9 (en:Method)
BE2014C010I2 (en:Method)